Get the Stockscreener App
17.50
0.17%
-0.03
After Hours:
17.85
0.35
+2.00%
Nurix Therapeutics Inc stock is traded at $17.50, with a volume of 1.05M.
It is down -0.17% in the last 24 hours and up +5.23% over the past month.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
See More
Previous Close:
$17.53
Open:
$17.54
24h Volume:
1.05M
Relative Volume:
0.95
Market Cap:
$1.81B
Revenue:
$71.78M
Net Income/Loss:
$-295.28M
P/E Ratio:
-5.5385
EPS:
-3.1597
Net Cash Flow:
$-271.85M
1W Performance:
+10.38%
1M Performance:
+5.23%
6M Performance:
+4.42%
1Y Performance:
+75.18%
1-Day Range:
$17.32
$17.85
1-Week Range:
$15.07
$17.85
52-Week Range:
$8.195
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
17.50 | 1.81B | 71.78M | -295.28M | -271.85M | -3.1597 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Therapeutics stock (US67079U1007): clinical pipeline and market reaction under the microscope - AD HOC NEWS
Nurix Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
NRIX Reiterated by BTIG -- Price Target Maintained at $30 - GuruFocus
Nurix Therapeutics (NRIX) moves 6.9% higher: Will this strength last? - MSN
A Look At Nurix Therapeutics (NRIX) Valuation After New NX-5948 Data And EHA Congress Selection - simplywall.st
Which Is a Better Investment, Kymera Therapeutics, Inc. or Nurix Therapeutics, Inc. Stock? - AAII
Nurix Therapeutics' (NRIX) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Nurix Therapeutics : NRIX - 24/7 Wall St.
Nurix Therapeutics Price Target Maintained With a $30.00/Share by BTIG - Moomoo
Nurix Therapeutics (NRIX) director awarded 31,250 stock options at $15.86 strike - Stock Titan
Nurix (NRIX) director granted stock options on 31,250 common shares - Stock Titan
Nurix Therapeutics (NRIX) director receives 31,250-share stock option grant - Stock Titan
Nurix Therapeutics (NRIX) director receives grant of 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director granted 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director gets 31,250 stock options at $15.86 - Stock Titan
Nurix Therapeutics (NRIX) director awarded 31,250 stock options - Stock Titan
Nurix Therapeutics Shareholders Back Directors and Governance Proposals - TipRanks
Vestal Point (NRIX) discloses 6.5M-share stake, 6.3% of float - Stock Titan
Nurix Therapeutics (NRIX) shareholders approve directors, PwC audit and say-on-pay - Stock Titan
Nurix Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Stifel Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Deep Track files 6.17% ownership in Nurix Therapeutics (NRIX) — 6.35M shares - Stock Titan
Nurix Therapeutics presents fresh preclinical and early clinical results for NX-5948 in CSU - Traders Union
Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting - Investing News Network
Did Nurix’s (NRIX) EHA Oral BTK Degrader Data Just Reframe Its Oncology Investment Narrative? - simplywall.st
Experimental hives pill from Nurix shows 25x lab potency vs remibrutinib - Stock Titan
(NRIX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Nurix Therapeutics stock (US67079U1007): Analysts see 144% upside potential - AD HOC NEWS
Nurix Therapeutics, Inc.Common stock (NQ: NRIX - FinancialContent
Nurix stock delivers 64% return after Fair Value identified opportunity By Investing.com - Investing.com Australia
Is Nurix Therapeutics (NRIX) Stock’s Premium P/S Multiple Fair After Recent Mixed Share Price Performance - Yahoo Finance
Nurix stock delivers 64% return after Fair Value identified opportunity - Investing.com
How Investors Are Reacting To Nurix Therapeutics (NRIX) Securing EHA Oral Slot For BTK Degrader Data - Yahoo Finance
Nurix Therapeutics to Participate in Upcoming Investor Conferences - Investing News Network
Oppenheimer Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Vanguard Group Inc. Purchases 1,460,736 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix CEO to speak at two May–June healthcare investor events - Stock Titan
Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress - The Manila Times
Nurix Therapeutics Announces Bexobrutideg Oral Presentation - TradingView
Nurix Therapeutics to present new Phase 1a b data on BTK degrader NX-5948 in CLL at EHA2026 - Traders Union
TradingKey - TradingKey
A Look At Nurix Therapeutics (NRIX) Valuation After Recent Share Price Move - Sahm
Nurix Therapeutics stock (US67079U1007): Biotech firm trading with deep losses and cash cushion - AD HOC NEWS
A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 - Yahoo Finance
Number of shareholders of Nurix Therapeutics, Inc. – NASDAQ:NRIX - TradingView
FMR LLC Boosts Position in Nurix (NRIX) — 5.54M Shares Reported - Stock Titan
Nurix CFO Hans van Houte sells $233k in company stock - Investing.com Canada
Houte Hans Van Sells 14,055 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NRIX) CFO sells 14,055 shares in planned trade - Stock Titan
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
[144] Nurix Therapeutics, Inc. SEC Filing - Stock Titan
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.98%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):